Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Changes in the Fiskars Group Leadership Team

Fiskars Corporation Stock Exchange Release January 18, 2022 at 10:00 (EET)     Changes in the Fiskars Group Leadership Team   Fiskars Group has made two changes to its Group Leadership Team to support the implementation of its previously announced growth strategy.   Charlene Patten Zappa has been appointed Executive Vice President, Business Area Terra and a member of the Fiskars Group Leadership Team. She will report to President and CEO Nathalie Ahlström and start in her position on January 18, 2022. She joins Fiskars Group from the J.M. Smucker Company, where

The Hakkapeliitta winter tire family is growing: New non-studded NOKIAN TYRES Hakkapeliitta® R5 offers unprecedented ice grip, silence and eco-friendly mobility for the Northern winter

Nokian Tyres  is continuing to renew its legendary Hakkapeliitta winter tire range. NOKIAN TYRES Hakkapeliitta® 10  has been a great success and now the world's northernmost tire manufacturer is publishing its new flagship products: Hakkapeliitta® R5 Nordic non-studded winter tires designed for passenger cars and SUVs.- Hakkapeliitta winter tires  are known around the world as the champions of demanding winter weather. The new

Cyxone takes next step in Multiple Sclerosis program engaging Contract Development & Manufacturing Organization for production of T20K

Cyxone (publ) announces today that the company has engaged a renowned European Contract Development & Manufacturing Organization (CDMO) for the scale-up and production of the active ingredient of its drug candidate T20K. The production will be performed in accordance with Good Manufacturing Practice (GMP), exploring a brand-new manufacturing method. The collaboration will initially cover method development and later supply material for use in non-clinical and clinical development activities.Cyxone is developing T20K, a peptide aimed for the treatment of multiple sclerosis (MS). Preclinical

Diagnostics pioneers Abacus Diagnostica, Kaivogen and Labrox are now together Uniogen

Three Finnish life science experts – Abacus Diagnostica, a frontrunner in molecular testing and rapid PCR test systems, Kaivogen, a specialist in immunoassays and antibody tests, and Labrox, an innovator of high technology laboratory instruments and diagnostic readers – announced in September 2021 that they are joining forces to form a global diagnostics pioneer. The share swap agreement between the companies has entered into force and the transaction has now been completed. The name of the new company is Uniogen Oy. The company is targeting the global market with a total solution under

Medivir’s MIV-818 obtains the International Nonproprietary Name fostroxacitabine bralpamide

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the World Health Organization (WHO) has selected the International Nonproprietary Name (INN) fostroxacitabine bralpamide as the official generic name for the company's patented candidate drug MIV-818, which is in clinical development in primary liver cancer. Medivir's main project, fostroxacitabine bralpamide (MIV-818), is the company’s proprietary candidate drug with a unique mechanism of action, which makes fostroxacitabine bralpamide attractive to be combined with a multitude of other drugs for the treatment

Invitation to presentation of year-end report 2021

Nobia will publish its year-end report for 2021 on Tuesday, February 1 at 08:30 CET. A webcasted telephone conference will be held the same day at 10.00 CET.Nobia’s President and CEO Jon Sintorn and CFO Kristoffer Ljungfelt will present the results and answer questions.The telephone conference will be webcasted live on Nobia’s website, or at https://edge.media-server.com/mmc/p/i4heo6dv Details for participation by telephone: Sweden:          +46 8 56 64 26 51UK:                 +44 33 33 00 08 04USA:               +1 631 913 1422Pin code:          8161 4899 # The

Azad Najar a speaker at the ICPM conference today

Today, 18 January, Realheart's founder Dr Azad Najar will be appearing at the ICPM conference in the United Arab Emirates. ICPM stands for International Conference of Pharmacy and Medicine and this is the second time Azad Najar has been invited. In addition, Realheart also has an exhibition space at the venue where the company's total artificial heart is presented.Dr Azad Najar is the founder of Realheart and the inventor behind the company's artificial heart. He is originally from Iraqi Kurdistan and has received a lot of attention for his innovation in this region. ''Worldwide, 64

Changes in the KONE Executive Board

KONE Corporation, stock exchange release, January 18, 2022 at 9.30 a.m. EET Changes in the KONE Executive Board Thomas Hinnerskov, Executive Vice President responsible for South Europe, Middle East and Africa, has decided to leave KONE for a position outside the company latest at the end of May 2022. Thomas has served as a member of KONE’s Executive Board since 2016, first as head of the Central and North Europe region and then head of the South Europe, Middle East and Africa region. The search for his successor has started. “I would like to thank Thomas for his valuable

Mandatory notification of trade

Anooj Unarket, Board member of Otello Corporation ASA, has on behalf of certain related parties, as of 17th January 2022, acquired interests in shares of Otello Corporation ASA. The balance of Anooj Unarket and related parties’ holdings after the transaction totals 27,064,137 shares. Please refer to the attached notification of trading for further details. This information is subject to disclosure requirements in regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act section 5-12.

Inhalation Sciences submits whitepaper to FDA aiming to establish DissolvIt® as an FDA-recommended standard research method in US

(Stockholm, 17 January 2022) Inhalation Sciences (ISAB) has submitted a white paper to the US FDA (Food and Drug Administration) aiming to validate its in vitro simulated lung model DissolvIt[®] as an FDA-recommended technology, and, ultimately, a new standard research method for inhaled drug research in the US. If approved, the FDA will co-fund the project for up to 250 KUSD (approx. 2.2 MSEK) on an annual basis for up to two years. A final decision on approval for the submitted whitepaper is expected in September 2022.Inhalation Sciences has submitted a formal whitepaper to the FDA’s

Nightingale introduces combination of its proprietary blood test and genomics: acquires Finnish genetic testing company Negen and launches international centre of excellence for genomic data analysis

Company release, Inside information18 January 2022 at 9:20 a.m. (EET) Nightingale Health Plc (“Nightingale”) announces today that the company will take a major step towards its mission of empowering people to make the best decisions for their own health by combining Nightingale’s proprietary blood test with genomics. This expansion is accelerated by acquiring a Finnish genetic testing company Negen Ltd. (“Negen”) and launching an international excellence centre focusing on genetic data analysis. The first products integrating Nightingale’s proprietary blood test and genomic data will

BioStock: Invent Medic focuses the organisation around sales

Since the launch of its first product, Efemia bladder support, Lund-based Invent Medic has slowly moved from being a pure development company to a company with a commercial focus. Newly-appointed CEO Anna Lindström is now conducting a reorganisation to further increase the sales focus. BioStock contacted Lindström to learn more about the organisational changes announced before Christmas.Read the full article at biostock.se:https://www.biostock.se/en/2022/01/invent-medic-focuses-the-organisation-around-sales/This is a press release from BioStock - Connecting Innovation & Capital. https://

LINK Mobility launches GSMA compliant RCS API globally

Oslo, Norway – 18 January 2022 LINK Mobility (LINK) is today announcing the global launch of its GSMA compliant Rich Communications Services (RCS) API. LINK’s single RCS API and integrated SaaS solutions enable brands to have increased reach and shortened time-to-market for RCS campaigning, Customer Care, and Natural Language Processing (NLP)/Artificial Intelligence (AI) chatbots. LINK is the RCS launch partner for mobile network operators in several countries and has direct access with over 80 mobile network operators globally for the provisioning of RCS messaging services.RCS, often

More efficient air filter with new design

Semcon is supporting Absolent Air Care Group in the development of a new type of modular carbon filter system for air purification. With the help of user studies and expertise in areas such as product design, mechanical design and flow calculation, Semcon’s team has developed a new design that makes the filter both more efficient and easier to handle.Absolent Air Care Group specialises in filters that purify polluted air from oil mist, oil smoke, gas and/or dust generated from various manufacturing processes. With Semcon’s help, the company is now developing the next-generation modular

Erja Sankari appointed as iLOQ’s Executive Vice President and Chief Operating Officer

Erja Sankari has been appointed as Executive Vice President and Chief Operating Officer as of 1st February, 2022. Erja will also become a member of iLOQ’s Management Team. Before joining iLOQ, Sankari has been working as Vice President of Global Supply Chain at Nokia. She will replace Esa Myllylä who will be retiring in 2022. Erja will be responsible for the comprehensive management and development of iLOQ’s global operations, internal practices and way of working and driving forward management systems. “iLOQ is a well-known and well-respected company. I am looking forward to

Hemsö acquires two nursing homes in Germany

Hemsö is continuing to grow in Germany and is acquiring two nursing homes in the state of Bavaria. The investment amount is EUR 26 million.The acquisitions comprise two nursing homes located in the historical cities of Waldkraiburg and Mühldorf just east of Munich in Bavaria. 20-year rental agreements have been signed with care provider Charleston for the two homes. “We are continuing to expand our portfolio of nursing homes in the state of Bavaria, which we are very happy about. We now own more than 70 nursing homes in total in Germany, including ten homes in Bavaria with about 900 beds,

Invitation to webcasted telephone conference of Cloetta AB´s year-end report 2021

Cloetta AB will publish the year-end report for the period 1 January – 31 December 2021 on Friday 28 January 2022 at 08.00 a.m. CET. Following this report Cloetta will organize a conference call with web presentation for media and the financial community.President and CEO Henri de Sauvage Nolting and CFO Frans Rydén will present and comment on the report. After the presentation there will be time for questions, both on the phone and in the web presentation. Time for the publication of the year-end reportFriday 28 January at 08:00 a.m. CET  Time for conference call and web

Invitation to conference call with web presentation of AcadeMedia's quarterly report for July – December 2021/22

AcadeMedia's quarterly report for July - December 2021/22 will be published at 08:00 CET on Tuesday 1 February. A web-cast telephone conference will be held at 09:30 CET the same day, where CEO Marcus Strömberg and CFO Katarina Wilson will present the report. The presentation will be held in English and can be followed on the web or over the phone. It will be followed by a Q&A session. To participate in the conference call, and thereby be able to ask questions, call one of the following numbers ten minutes before the start of the call: SE: +46 8 505 583 74UK: +44 33 3300 9273US:

TIE Kinetix Earns ISO 27017 and ISO 27018 Certifications

TIE Kinetix , a leader in 100% supply chain digitalization, announced today that the company is now ISO 27017 and ISO 27018 certified. In addition to the company’s existing ISO 27001 certification, the new certifications raise the bar for information security, guaranteeing enhanced cloud information security and privacy in the cloud. The accomplishment marks a significant achievement for TIE Kinetix at a time when supply chain attacks are on the rise and enhanced security is a top IT initiative.An estimated 80% of cyber attacks worldwide occur through supply chains (

Liselotte Haglind appointed new CFO

Liselotte Haglind has been appointed CFO of Projektengagemang Sweden AB (publ). She joins the company from KPMG Sverige, where she is CFO and COO. The current CFO Peter Sandberg is leaving the company.Liselotte Haglind has over 20 years of experience from leading positions in finance and business. She joins the company from KPMG Sverige, where she is CFO and COO, before that she worked for eight years as CFO at Sweco Sverige AB. Liselotte Haglind will be part of the company's management team and will take up her position no later than July 17, 2022. – We are on an exciting growth journey

Esmaeilzadeh Holding has successfully issued senior unsecured bonds of SEK 1.2 billion

Esmaeilzadeh Holding AB (publ) (“EHAB” or the “Company”) has successfully issued inaugural senior unsecured bonds in the amount of SEK 1.2 billion, under a total framework of SEK 2.4 billion (the “Bonds”). The Bonds carry a floating interest rate of 3m STIBOR + 750 basis points with final maturity in January 2025. The net proceeds from the Bonds will primarily be used to finance acquisitions within the group.   The bond issue was subscribed by approximately 80 investors of which the five largest manage in aggregate SEK 1,350 billion.   “I am grateful for the interest and strong

MSAB’s Net Sales and Operating Result in the Fourth Quarter of 2021 are expected to exceed market expectations

Micro Systemation AB (publ) improves net sales and operating profit in the fourth quarter of 2021 and are expected to exceed market expectations.MSAB, a world leader in forensic technology for extracting and analyzing data in seized mobile devices, has had a high level of delivery activity during the fourth quarter. Net sales in the fourth quarter of 2021 are estimated to amount to approximately SEK 108 million, which corresponds to a growth of 62% compared with the fourth quarter of 2020. The operating profit for the fourth quarter of 2021, which has not yet been finally determined, is

Fortum initiates wind power cooperation in Russia with Bank GPB

FORTUM CORPORATION INVESTOR NEWS 18 JANUARY 2022 9:00 EET Fortum is initiating cooperation in wind power generation in Russia with Bank GPB. For this purpose, 1.3 GW portfolio of wind projects is being transferred from the Fortum-Rusnano Wind Investment fund (50/50 joint venture) to a joint venture recently established with Bank GPB. Upon the transfer, the joint venture of Fortum-Rusnano Wind investment fund will be dissolved. Fortum holds the investment fund’s most recently (wind auction in September 2021) awarded 1.4 GW of wind capacity for new wind power generation to be

Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects Reported

Lund, Sweden, January 18, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the on-going OPTIMIZE-1 clinical Phase Ib/II trial with the company’s lead asset, mitazalimab. All patients in the 450 µg/kg cohort have been dosed and there have been no adverse effects related to study medication has been reported. Dosing of the 900 µg/kg cohort has been initiated. The Phase 1b part of the study is expected to be completed during Q1 2022. OPTIMIZE-1, an open-label, multi-center phase Ib/II study is assessing the safety and efficacy of mitazalimab in combination

There are no items matching the current filter
There are no more items matching the current filter
Back to top